Powered by

Patients stuck in corporate fight against generic drugs

Jan 10, 2019 - The Washington Post

Health-care and government officials are growing concerned that the makers of the most advanced drug therapies are using scare tactics to ward off emerging generic versions of their products, a bid to protect profits that has enormous implications for the nation's efforts to control health-care costs.

Doctors, drug companies and the nation's top drug regulator say the companies that make costly name-brand biologic drugs, which are grown from living cells, are sowing doubt about the wisdom ...